Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nifedipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 6/20 | 0.97 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 0.97 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 0.97 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.97 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.97 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.97 |
| ▸ | SCN1A | P35498 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nifedipine SCHEMBL1172946 | 0.99 | ADORA3 (1.00) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL29349595 | 0.99 | ADORA3 (1.00) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL3968 | 0.99 | ADORA3 (1.00) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL5694031 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL27076589 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL27076587 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL8851397 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL27961697 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL3858071 | 0.97 | ADORA3 (0.97) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 | |
| Nifedipine SCHEMBL9759614 | 0.95 | ADORA3 (0.93) | ADORA3CYP1A2CACNA1CCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2263670-B1 | Use of angiotensin II receptor antagonists in order to increase insulin sensitivity | BOEHRINGER INGELHEIM PHARMA (DE) | 2015-09-09 | — | — | EP | claimed |
| CN-111643473-B | Nifedipine sustained release tablet and preparation method thereof | 华润双鹤利民药业（济南）有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114384170-A | Method for determining concentration of amlodipine in blood plasma by liquid chromatography-mass spectrometry | 安徽万邦医药科技股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-113197851-A | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of use thereof | 辛纳吉勒公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-107847722-B | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of use thereof | 辛纳吉勒公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-107213138-B | Method and pharmaceutical composition for treating hypertension by timed release of drugs | 北京罗诺强施医药技术研发中心有限公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-111643473-A | Nifedipine sustained release tablet and preparation method thereof | 华润双鹤利民药业（济南）有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3191105-A1 | SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF | Braintree Laboratories, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040733-A1 | SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF | BRAINTREE LABORATORIES, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| CN-102203074-A | Aryl GPR119 agonists and uses thereof | METABOLEX INC | 2011-09-28 | — | — | CN | disclosed |
| CN-102026636-A | Oxymethylene aryl compounds and uses thereof | METABOLEX INC | 2011-04-20 | — | — | CN | disclosed |
| CN-101754962-A | N-azacyclic substituted pyrrole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 for the treatment of diabetes and metabolic disorders | METABOLEX INC | 2010-06-23 | — | — | CN | disclosed |
| CN-101616586-A | The heterocyclic receptor agonists of treatment diabetes and metabolic disorder | METABOLEX INC | 2009-12-30 | — | — | CN | disclosed |
| CN-101095682-A | Oral preparations of ivabradine or the medical salt thereof | BEIJING BENCAO TIANYUAN MEDICA (CN) | 2008-01-02 | — | — | CN | disclosed |
| US-5650394-A | Use of urinastatin-like compounds to prevent premature delivery | ADEZA BIOMEDICAL (US) | 1997-07-22 | — | — | US | disclosed |
| EP-0732932-A1 | USE OF URINASTATIN-LIKE COMPOUNDS TO PREVENT PREMATURE DELIVERY | ADEZA BIOMEDICAL (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996026273-A1 | POLYPEPTIDES DERIVED FROM URINASTATIN HAVING CALCIUM CHANNEL BLOCKING ACTIVITY AND THEIR USE TO DELAY PREMATURE DELIVERY | ADEZA BIOMEDICAL CORPORATION (US) | 1996-08-29 | — | — | WO | disclosed |
| WO-1995012406-A9 | USE OF URINASTATIN-LIKE COMPOUNDS TO PREVENT PREMATURE DELIVERY | — | 1996-06-13 | — | — | WO | disclosed |
| WO-1995012406-A1 | USE OF URINASTATIN-LIKE COMPOUNDS TO PREVENT PREMATURE DELIVERY | ADEZA BIOMEDICAL (US) | 1995-05-11 | — | — | WO | disclosed |
| WO-1995011894-A1 | HISTAMINE H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF | THE UNIVERSITY OF TOLEDO (US) | 1995-05-04 | — | — | WO | disclosed |